Publications

Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.
Clin Rheumatol 2017 Dec 15;36(12):2839-2845. Epub 2017 Sep 15.
Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.


Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.
Medicine (Baltimore) 2017 Oct;96(42):e8180
aRheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila bClinical Medicine and Rheumatology Department, Campus Bio-Medico University of Rome, Rome cRheumatology Section, Department of Internal Medicine, University of Palermo, Palermo dRheumatology Section, Department of Clinical and Experimental Medicine, Second University of Naples, Naples eRheumatology Section, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia fDepartment of Experimental and Clinical Medicine, University of Florence, Florence gRheumatology Section, L. Sacco University Hospital, Milan hSystemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.



Computed Tomography and MR Imaging in Rheumatoid Arthritis.
Radiol Clin North Am 2017 Sep 12;55(5):997-1007. Epub 2017 Jun 12.
Diagnostic and Interventional Radiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, L'Aquila, Coppito 67100, Italy.

Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.
Medicine (Baltimore) 2017 Aug;96(34):e7896
aDivision of Rheumatology, Department of Biotechnological and Applied Clinical Science, University of L'Aquila, L'Aquila bDepartment of Health Sciences, University of Catanzaro "Magna Graecia", Catanzaro cDivision of Rheumatology, Department of Internal Medicine, University of Palermo, Palermo, Italy.


Interstitial lung disease in systemic sclerosis: current and future treatment.
Rheumatol Int 2017 Jun 6;37(6):853-863. Epub 2017 Jan 6.
Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, Delta 6 Building, Via dell'Ospedale, 67100, L'Aquila, Italy.



Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers.
BMC Med 2016 Dec 1;14(1):194. Epub 2016 Dec 1.
Rheumatology Section, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, Delta 6 Building, Via dell'Ospedale, 67100, L'Aquila, Italy.


IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?
Expert Rev Clin Immunol 2016 Aug 12;12(8):849-55. Epub 2016 Apr 12.
a Division of Rheumatology, Department of Biotechnological and Applied Clinical Science , School of Medicine, University of L'Aquila , L'Aquila , Italy.



Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis.
J Rheumatol 2016 Jul 1;43(7):1340-9. Epub 2016 Jun 1.
From the Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, and the Department of Applied Clinical Sciences and Biotechnology, General Pathology Unit, University of L'Aquila, L'Aquila; Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo, Palermo, Italy.P. Cipriani, MD, PhD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; P. Di Benedetto, PhD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; P. Ruscitti, MD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; V. Liakouli, MD, PhD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; O. Berardicurti, MD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; F. Carubbi, MD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; F. Ciccia, MD, PhD, Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo; G. Guggino, MD, Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo; F. Zazzeroni, PhD, Department of Applied Clinical Sciences and Biotechnology, General Pathology Unit, University of L'Aquila; E. Alesse, MD, PhD, Department of Applied Clinical Sciences and Biotechnology, General Pathology Unit, University of L'Aquila; G. Triolo, MD, PhD, Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo; R. Giacomelli, MD, PhD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School


The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.
J Rheumatol 2015 Oct 15;42(10):1808-16. Epub 2015 Aug 15.
From the Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, and the Department of Applied Clinical Sciences and Biotechnology, General Phatology Unit, University of L'Aquila, L'Aquila; Medical and Scientific Direction, Actelion Pharmaceuticals Italy, Imola, Italy; Drug Discovery Department, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.P. Cipriani, MD, PhD; P. Di Benedetto, PhD; P. Ruscitti, MD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; D. Capece, PhD; F. Zazzeroni, PhD, Department of Applied Clinical Sciences and Biotechnology, General Phatology Unit, University of L'Aquila; V. Liakouli, MD, PhD; I. Pantano, MD; O. Berardicurti, MD; F. Carubbi, MD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila; G. Pecetti, MD; S. Turricchia, MD, Medical and Scientific Direction, Actelion Pharmaceuticals Italy; E. Alesse, MD, PhD, Department of Applied Clinical Sciences and Biotechnology, General Pathology Unit, University of L'Aquila; M. Iglarz, PhD, Drug Discovery Department, Actelion Pharmaceuticals Ltd.; R. Giacomelli, MD, PhD, Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila.

Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Arthritis Res Ther 2015 Sep 10;17:247. Epub 2015 Sep 10.
Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila, Delta 6 Building, Via dell'Ospedale, 67100, L'Aquila, Italy.

Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature.
J Med Case Rep 2015 Jun 2;9:123. Epub 2015 Jun 2.
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Rheumatology Unit, delta 6 building, PO Box 67100, L'Aquila, Italy.

Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study.
Rheumatology (Oxford) 2015 May 6;54(5):792-7. Epub 2014 Oct 6.
Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Rheumatology Unit, University of Brescia, Brescia, Rheumatology Unit, University of Ferrara, Ferrara, Rheumatology Unit of the Second University of Naples, Naples, Rheumatology Unit, Polytechnic University of the Marche, Jesi, Ancona, Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Rheumatology Unit, Department of Clinical Medicine and Immunological Science, University of Siena, Siena, Division of Rheumatology, Department of Biomedicine, University of Florence, Florence, Rheumatology Unit, Department of Clinical and Experimental Medicine, University Federico II, Naples, Division of Rheumatology, Misericordia e Dolce Hospital, Prato, Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Rheumatology Unit, University of Bari, Bari, Rheumatology Unit, G Pini Hospital, Milan, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Rome, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera and Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.



Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine.
Angiogenesis 2013 Jul 15;16(3):595-607. Epub 2013 Feb 15.
Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, Delta 6 Building, Via dell'Ospedale, 67100 L'Aquila, Italy.


Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis.
Fibrogenesis Tissue Repair 2014 15;7:13. Epub 2014 Sep 15.
Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, School of Medicine, University of L'Aquila, Delta 6 Building, Via dell'Ospedale, 67100 L'Aquila, Italy.




OF